Ann: $2.4 Million Fully Underwritten Rights Issue, page-43

First 43 Last

Share
Profile

Follow
beefarmer

15,824 Posts.

1447

19/01/18

21:23

Post #: 30429079
Share

Originally posted by brainybull ↑

Dear Beef
The cap raise presentation notes that 2 sets of results relating to PAT-DX1 are due in Jan 2018. There are only 8 trading days left in Jan 2018. Therefore the SP will rise n expectation of good results. It does not matter that the testing is in a glass dish because in September 2017 the SP rose 700% to 3.3 cents in a couple of days based on results in a glass dish. And I can't see why it cannot do so again especially given the low market cap and reduced funding risk which was holding the SP down. Now that the share issue has been underwritten and money will come in the Bank. I also hoped that the announcements were made after the share issue is fully finalised and the path is clear.

The existence of PAB depends on PAT-DX1. Management must have some knowledge how the testing is progressing. I don't think management will blatantly lie.

The SP has not been rising because there is almost no supply until 3.3 cents. Only $40,000 worth of shares are on the sell side until we reach 3 cents.

I may be foolish, but I have committed a lot in PAB only because it has the potential to change my financial life. I have been investing for over 20 years only in species which could get me millions and my track record has been really bad. But with this low market cap and cancer cure block buster potential, I just think PAB is on something big and this will get me my millions. Warren Buffet said to hit the big time "sell when the market is greedy and buy when the market is fearful". I am buying now and will sell half by holdings at the IND application/ recruitment stage. I expect that the SP will be at least 20 cents at the IND stage and perhaps much higher.
Brainy.

Expand

BEAUTIFULLY EXPLAINED........................thankyou very much.

If the product is that good, buyers will move in and take them out. See MYQ.

This may be occurring now.

Twenty years ........have you bought any BOT because if you have not, then do so.
That's all I will say on that. You obviously do your research.

Thanks again.

PAB Price at posting: 2.1¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 2 more messages in this thread...

First 43 Last

Add PAB (ASX) to my watchlist

(20min delay)
Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $6.172M

Open	High	Low	Value	Volume
0.3¢	0.3¢	0.3¢	$19.82K	6.607M

Buyers (Bids)

No.	Vol.	Price($)
36	29828727	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	27089307	15

View Market Depth

No.	Vol.	Price($)
36	29828727	0.003
24	35131332	0.002
13	50551999	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	27089307	15
0.005	11004512	9
0.006	3371450	5
0.007	6601356	5
0.008	1221910	4

Last trade - 16.10pm 07/10/2024 (20 minute delay)

PAB (ASX) Chart

Ann: $2.4 Million Fully Underwritten Rights Issue, page-43

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: $2.4 Million Fully Underwritten Rights Issue, page-43

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News